Funding rounds: SkylineDx, Filterlex Medical, TandemAI, Oncorena

France: Lysogene, a phase 3 gene therapy platform company targeting central nervous system diseases, has entered into a €15m US$17.03m) loan agreement with the European Investment Bank (EIB). The loan comes in three tranches: a first tranche of €3m that can be unconditionally drawn down and two other tranches of €5m and €7m available upon…

You must be a HMI Subscriber to view this content.

Subscribe Now »